LOXL2 Inhibitors and Breast Cancer Progression

Blocking LOXL2 and TGFβ1 signalling induces collagen I turnover in precision-cut lung slices derived from patients with idiopathic pulmonary fibrosis

(2021) Ying Wei et al.   THORAX

Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours

(2021) Yordanos F.I. Setargew et al.   Cancers

Elevated intracellular copper contributes a unique role to kidney fibrosis by lysyl oxidase mediated matrix crosslinking

(2020) Yang-yang Niu et al.   Cell Death & Disease

Lysyl oxidase induces epithelial–mesenchymal transition and predict intrahepatic metastasis of hepatocellular carcinoma

(2019) Naoki Umezaki et al.   CANCER SCIENCE

Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure–Activity Relationships

(2019) Leo Leung et al.   JOURNAL OF MEDICINAL CHEMISTRY

Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer

(2019) Chunying Wang et al.   NEOPLASIA

Upregulated LOX and increased collagen content associated with aggressive clinicopathological features and unfavorable outcome in oral squamous cell carcinoma

(2019) Miao Yu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth

(2019) Deborah A. Smithen et al.   JOURNAL OF MEDICINAL CHEMISTRY

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

(2019) J. P. Cebrià-Costa et al.   ONCOGENE

Identification of Prognostic Candidate Genes in Breast Cancer by Integrated Bioinformatic Analysis

(2019) Wang et al.   Journal of Clinical Medicine

Stimulation of cell invasion by the Golgi Ion Channel GAAP/TMBIM4 via an H2O2-Dependent Mechanism

(2019) Nuno Almeida et al.   Redox Biology

Overexpression of Lox in triple-negative breast cancer

(2018) Cornelia Leo et al.   Annals of Diagnostic Pathology

Inhibition of the lox enzyme family members with old and new ligands. selectivity analysis revisited

(2018) István Hajdú et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state

(2018) Xi Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

LOXL2 promotes vasculogenic mimicry and tumour aggressiveness in hepatocellular carcinoma

(2018) Bing Shao et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis

(2018) Heidi Schilter et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition

(2018) Olivier G. de Jong et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The manganese(III) porphyrin MnTnHex-2-PyP5+ modulates intracellular ROS and breast cancer cell migration: Impact on doxorubicin-treated cells

(2018) Ana Flórido et al.   Redox Biology

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

(2017) Naoki Ikenaga et al.   GUT

Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis

(2017) Ying Wei et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)

(2017) Martin W. Rowbottom et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of MetastaticKRASMutant Colorectal Adenocarcinoma

(2017) J. Randolph Hecht et al.   ONCOLOGIST

A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma

(2017) Al B. Benson et al.   ONCOLOGIST

Association between lysyl oxidase and fibrotic focus in relation with inflammation in breast cancer

(2017) Young Jeong et al.   Oncology Letters

Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface

(2017) HaoRan Tang et al.   Nature Communications

Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer

(2017) Joan Chang et al.   Oncotarget

Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases

(2017) Chen Rachman-Tzemah et al.   Cell Reports

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial

(2017) Ganesh Raghu et al.   Lancet Respiratory Medicine

European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)

(2017) Javier Egea et al.   Redox Biology

Tumor Cell Invasion Can Be Blocked by Modulators of Collagen Fibril Alignment That Control Assembly of the Extracellular Matrix

(2016) Moran Grossman et al.   CANCER RESEARCH

Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis

(2016) Thomas R. Cox et al.   CANCER RESEARCH

Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer

(2016) Ping Zhan et al.   Clinical Respiratory Journal

Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial

(2016) Eric G. Meissner et al.   LIVER INTERNATIONAL

The effect of LOXL2 in hepatocellular carcinoma

(2016) Linghong Wu et al.   Molecular Medicine Reports

The function and mechanisms of action of LOXL2 in cancer (Review)

(2015) LINGHONG WU et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

LOXL2 Status Correlates with Tumor Stage and Regulates Integrin Levels to Promote Tumor Progression in ccRCC

(2014) H. Hase et al.   MOLECULAR CANCER RESEARCH

LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients

(2013) Sung Gwe Ahn et al.   BREAST CANCER RESEARCH AND TREATMENT

Post-translational Modifications of Recombinant Human Lysyl Oxidase-like 2 (rhLOXL2) Secreted fromDrosophilaS2 Cells

(2013) Li Xu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of Heterochromatin Transcription by Snail1/LOXL2 during Epithelial-to-Mesenchymal Transition

(2013) Alba Millanes-Romero et al.   MOLECULAR CELL

LOXL2 in epithelial cell plasticity and tumor progression

(2012) Amparo Cano et al.   Future Oncology

Inactivation of lysyl oxidase by β-aminopropionitrile inhibits hypoxia-induced invasion and migration of cervical cancer cells

(2012) XIAOXIAO YANG et al.   ONCOLOGY REPORTS

Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane

(2011) M. Bignon et al.   BLOOD

LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution

(2011) H. E. Barker et al.   CANCER RESEARCH

Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas

(2011) Gema Moreno-Bueno et al.   EMBO Molecular Medicine

Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation

(2011) C. C.-L. Wong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Congenital cutis laxa and lysyl oxidase deficiency

(2010) Abbas Khakoo et al.   CLINICAL GENETICS

Modulation of Lysyl Oxidase-like 2 Enzymatic Activity by an Allosteric Antibody Inhibitor

(2010) Hector M. Rodriguez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Two macrocyclic pentaaza compounds containing pyridine evaluated as novel chelating agents in copper(II) and nickel(II) overload

(2010) Ana S. Fernandes et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin

(2010) Young-Mi Kim et al.   MOLECULAR BIOLOGY REPORTS

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

(2010) Vivian Barry-Hamilton et al.   NATURE MEDICINE

In search of a new therapeutic target for the treatment of genetically triggered thoracic aortic aneurysms and cardiovascular conditions: insights from human and animal lathyrism

(2010) H. M. F. Sherif   Interactive Cardiovascular and Thoracic Surgery

Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling

(2009) Kandice R. Levental et al.   CELL

Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells

(2009) Peter Hollosi et al.   INTERNATIONAL JOURNAL OF CANCER

The Lysyl Oxidase Inhibitor, β-Aminopropionitrile, Diminishes the Metastatic Colonization Potential of Circulating Breast Cancer Cells

(2009) Alla Bondareva et al.   PLoS One